Search

Search Constraints

You searched for: Author/Creator Maesaka, Kazuki

Search Results

1. Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment. Issue 5 (9th March 2021)

2. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Issue 7 (25th April 2022)

3. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Issue 4 (22nd December 2022)

4. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Issue 3 (28th December 2021)

5. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Issue 3 (1st December 2019)

6. Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. Issue 11 (31st August 2020)

7. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Issue 1 (17th January 2023)

8. Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. Issue 9 (3rd August 2020)